Articles from Trinity Life Sciences

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, introduced its artificial intelligence (AI) algorithm which accurately predicted revenue outcomes for over 90% of U.S. drug launches, far exceeding the accuracy of Wall Street analyst consensus at the time of launch (<60%). Trinity’s latest white paper in its Industry Impact Series, titled Predicting Winners: AI-Powered Portfolio Management, explores the use of AI to improve portfolio decision-making in the life sciences industry.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, announces a dedicated Value Center of Excellence (COE) that provides end-to-end partnership along the value journey to Market Access and Health Economics and Outcomes Research (HEOR) teams, from strategy to communication. The COE approaches U.S. and global value work through a uniquely integrated combination of market access and HEOR expertise. Trinity’s Value COE is pioneering the integration of health equity into value strategy.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, today announces an enhancement to its HTA Vision offering that swiftly extracts relevant information from health technology assessments (HTAs) and Trinity expert analyses, streamlining the information-gathering process within any therapeutic area or drug class. By not only locating but also summarizing key information with generative AI (GenAI), HTA Vision transforms complex documents into clear, comprehensive overviews.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, introduces a focused Marketing Communications Insights (MarCom Insights) Center of Excellence (COE) that assesses pre- and post-launch educational and marketing materials focused on healthcare professionals (HCPs) and patients. The COE leverages behavioral science and AI with an omnichannel lens to enable precise, personalized communications over a variety of channels.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, looks at AI from the lens of business value, solving business problems with integrated intelligence. Trinity’s digital products and AI solutions are tightly integrated across the scope of the Company’s offerings, providing insights to commercial and medical leaders and orchestrating customer engagement. To lead these important initiatives, Trinity has appointed Jonathan Jenkins, formerly of McKinsey & Company’s QuantumBlack, to accelerate its AI and digital efforts.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, released its fourth annual TGaS Digital Marketing Competency Report assessing the digital marketing presence for patients across 150+ biopharma brands. The study evaluates the brands across five categories and more than 100 characteristics to establish a brand digital competency ranking.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, recommends a transformational approach to measure the impact of Field Medical Affairs in its new white paper titled Measuring the Impact of Field Medical Affairs.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, delivers life science companies industry-specific data orchestration with TrinityEDGE, Commercial Data Foundations.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, reveals that 50% of the 2023 U.S. pharmaceutical launch class underperformed their pre-launch first year forecast while 39% overperformed. This is an improvement from prior years, with 54% underperforming and 35% overperforming when evaluating new product launches in the U.S. from 2020–2023. Progress was driven by a notable increase in overperformance by specialty and large market products and first launch companies.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, finds that thirty-two percent of life science marketing and analytics teams report not knowing about or not using key performance indicators (KPIs) to inform shifts in investment.*

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, discusses approaches and functional plans that support the holistic, cross-functional strategies required for success in a new white paper, titled Solving a Pervasive Challenge: Breaking Down Silos in Life Sciences.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, announces new Customer Engagement solutions leveraging both Trinity’s deep commercial insight and recognized technology platform. The new offerings are designed to help life sciences organizations with novel customer engagement solutions including adaptive segmentation, rep-directed guidance including target patient triggers, deep insights on healthcare provider (HCP) preferences and orchestration of activation across channels. At the helm of these new offerings is Nancy Phelan, Senior Vice President and Head of Customer Engagement.

Inc. revealed today that Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, has been included on the Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy’s most dynamic segment—its independent, entrepreneurial businesses. Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, Patagonia and many other household-name brands gained their first national exposure as honorees on the Inc. 5000.

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, announces the appointment of Aparna Deshpande to Senior Partner and Head of Analytics & Insights. Ms. Deshpande had previously been Senior Partner and Head of Insights for the Company. The added responsibility of leading the Analytics business represents the overall benefits that life science companies can achieve when weaving the power of insights with accurate analytics.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, release research on clinical trial diversity with a focus on racial and ethnic minorities in a new white paper, titled Diversity in Clinical Trials: Life Sciences Initiatives and Challenges in Light of the FDA’s Latest Guidance. The paper outlines initiatives that are being undertaken at the corporate level to improve the diversity of clinical trials, the effectiveness of those initiatives and the impact of the U.S. Food and Drug Administration (FDA)’s guidance to improve diversity now and in the future.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced the winners of the TGaS Advisors Best of Benchmark (BoBs) Awards. The Awards, which are given annually for operational excellence within the pharmaceutical industry, were presented to teams at AbbVie, Astellas Pharma Inc., AstraZeneca, Incyte, Eli Lilly and Company and Novo Nordisk. The BoBs are based on TGaS benchmarking of large, midsize and emerging life sciences companies.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, today launched a new solution that accurately predicts stakeholder behavior providing deeper insights. For the first time, life sciences companies can incorporate real-world, healthcare professional (HCP)-specific prescribing behaviors with primary market research (PMR). This integration provides a view of what physicians are currently doing that is independent of what those physicians may say in market research studies.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, unveils its Industry Impact Series—a thought leadership series designed to identify key issues that will revolutionize the way therapeutics are developed and commercialized in the years ahead. The first installment of the series, a white paper entitled Picking Winners: Portfolio Management for a New Era, explores the challenges biopharma companies face in selecting the right therapies to advance into the clinic and the market.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announces the availability of its Annual State of Global Market Access white paper, an evaluation of six key global market access trends that life sciences companies need to be monitoring in 2024 and beyond. The paper explores the consequences of new therapeutic advances and policies aiming to control costs globally and the implications for pharmaceutical manufacturers. An upcoming webinar entitled Annual State of Global Market Access provides a deeper review of a few trends highlighted in the white paper—the continued expansion of cell and gene therapy, evolving evidence expectations, and increased market delays and withdrawals due to low reimbursement.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, today launched Brand Insights AI to develop, share and refine insights across the full breadth of biopharmaceutical brand research. Designed by experts with deep technical knowledge and expertise in the nuances of life sciences research, it allows insights and analytics teams to answer brand questions in seconds.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announces the availability of its Trinity Annual Drug Index white paper, an evaluation of the commercial performances over three years of 58 novel drugs approved in 2020. An upcoming webinar Learn From the Past – Launch Better Tomorrow will help companies apply learnings from these past launches to inform their commercialization strategies.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, reports that China’s 2022 National Reimbursement Drug List (NRDL) demonstrates promising pricing and access opportunities for innovative drugs with significant clinical benefit. The new white paper “2022 NRDL Pricing Implementation and Access Outcomes in China” provides an in-depth analysis and key takeaways of the update.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy (C&GT) Center of Excellence (COE) that supports life sciences companies in successfully commercializing a C&GT asset. The unique challenges and opportunities in commercializing C&GT are markedly different from traditional one-size-fits-all products, requiring innovation and a change in the traditional commercial model.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, has made available its TGaS Advisors’ brief “What You Need To Know Now To Be Prepared for 2024” based on highlights presented at the TGaS Advisors’ 2023 Fall Client Summit. The TGaS 2023 Fall Client Summit included 16 function-specific sessions in the areas of commercial operations, market access and medical affairs. The sessions were held virtually in October and November with over 500 attendees from 100 life sciences companies, the largest virtual Summit to date.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, released its third annual TGaS Digital Marketing Competency Report assessing 160+ biopharma brands through the lens of digital marketing patient/caregiver experiences. The study evaluates the brands across five categories and more than 100 characteristics to understand each one’s digital marketing presence and establish a brand digital competency ranking.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, maps out investment strategies and tactics to calibrate a patient-centric approach in rare disease in its new advisory brief. The brief outlines four pillars that focus resource allocation, improve patient care and provide differentiated patient partnership. Within the nuances of each disease, companies must effectively address challenges around identifying and treating patients—as well as providing long-term support.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, today announced the appointment of Rajeev Rangachari to serve as the Company’s first-ever Chief Technology Officer (CTO). Mr. Rangachari brings significant experience in building flexible, scalable solutions for life sciences organizations to Trinity.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces the first method that incorporates Healthcare Professionals (HCP)-specific real-world behaviors to improve share calibration for forecasting. The method, called “tethering,” uses real-world prescribing behaviors to calibrate share estimates from primary market research (PMR) by connecting them to the current market scenario. This real-world calibration at the HCP level significantly improves share estimation without compromising survey data integrity.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, has made available its TGaS Advisors’ white paper “The Globalization Marathon: Is Pharma Commercial Operations Moving to a Full Global Operating Model?” The white paper is based on primary research conducted by TGaS with a subset of its ~100 member companies’ Commercial Operations leaders representing large, mid-size and emerging pharmaceutical companies operating in global markets.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announces the availability of Trinity Launch Accelerator 2.0 to provide smart, efficient launch planning with customized, tech-enabled support. Built and powered by Trinity’s Launch Center of Excellence (COE), Launch Accelerator 2.0 is an easy-to-use cloud-based project management tool that leverages recent “real world” launches to guide cross-functional Global Launch and Project Management Office (PMO) teams.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, has announced its Board of Advisors, a group of independent, expert advisors that will help advance Trinity’s mission.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, was identified as a Sample Vendor in four sections within the July 2023 Gartner Hype Cycle for Life Sciences Commercial Operations report. The sections where Trinity was named are:

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announces the creation of the Trinity Healthcheck suite to identify areas of opportunity and provide comprehensive, actionable recommendations for enhancing overall readiness and performance. The assessments objectively evaluate the current state of a life sciences company’s operations, including strategy, processes, technology and talent. The suite includes three types of assessments with the following areas of focus and recommendation:

Inc. revealed today that Trinity Life Sciences, a leader in global life sciences commercialization solutions, was named to the Inc. 5000 list for the third year in a row. The prestigious ranking provides a data-driven look at the most successful companies within the economy’s most dynamic segment – its independent, entrepreneurial businesses.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced the availability of its Trinity Annual Drug Index, an evaluation of the actual commercial performances over 3 years of 53 novel drugs approved in 2019.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announces the launch of the Market Intelligence Dashboard to meet the needs of Competitive Intelligence (CI) teams and their end users. Built and powered by Trinity’s Dynamic Market Intelligence Center of Excellence (COE), the Market Intelligence Dashboard provides a steady stream of curated data and insights through the power of AI-enabled automation and the expertise of a dedicated team of “Intelligence Strategists.”

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced today the appointment of Leslie Orne as Chief Executive Officer (CEO) effective July 1. Ms. Orne, who is currently the President and Chief Commercial Officer at Trinity, succeeds David Fitzhenry, who has held various leadership roles at Trinity for 26 years. Mr. Fitzhenry will remain active with the Company as a strategic advisor and member of the Board of Directors.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced the winners of the TGaS Best of Benchmark (BoBs) Awards. The Awards, which are given for operational excellence within the pharmaceutical industry, were presented to teams at Bayer, Genentech, Novo Nordisk, Sanofi, Sunovion and UCB. The BoBs are based on TGaS benchmarking of large, midsize and emerging life sciences companies.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announces enhancements to its cross-functional forecasting tool, Trinity CloudCast™. Forecasting within life sciences companies is a collaborative exercise driving vital decisions that impact both the near- and long-term future of organizations in their entirety. CloudCast is an online solution that establishes structured data and information flows to support streamlined, confident business discussions. The application provides users with the option of working in an Excel file or editing on a web-based interface.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, and WhizAI, a leader in AI-powered analytics for life sciences and healthcare, today announced a partnership that allows life sciences companies to quickly and easily generate and share AI-driven insights. The partnership allows WhizAI’s unique conversational AI and visualization platform to be offered in conjunction with Trinity’s best-in-class data management solutions and advisory services. WhizAI’s augmented analytics can be layered on top of Trinity’s enterprise reporting platforms to bring insights to more stakeholders throughout the organization. Commercial teams in life sciences can leverage the combined offerings for a variety of use cases, such as field sales analytics, longitudinal patient claims analytics, market access analytics, patient services analytics and more.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces Trinity Omnichannel Promotional Excellence, a suite of scalable solutions for commercial life sciences teams focused on planning, executing and optimizing omnichannel initiatives. The portfolio includes technology, analytics, data science and business intelligence tools and services that address multiple life sciences omnichannel needs.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces a Patient Services Center of Excellence (COE) that offers life sciences companies data-driven insights, strategy and solutions to power patient-centric support services. Developing and executing high-impact Patient Support Services (PSS) is important as manufacturers strive to create differentiation through patient-centric customer experiences.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, has launched the TGaS Advisors’ Agency Optimization Benchmark. The new benchmark helps life sciences companies understand how their utilization of agencies compares to industry peers.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announces the creation of Trinity Performance Tracking, a new Center of Excellence (COE) that focuses on a comprehensive approach to stakeholder perception tracking and integrates primary and secondary data to view the total context. Evaluating the impact of market events, advocacy, promotion and messaging around each product is an essential need for Marketing and Brand leaders within the life sciences industry—but interpretation of trackers like ATUs (Awareness, Trial and Usage) tends to fall into a routine at an individual brand level.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces Trinity Contract Analytics, an offering that enhances U.S. payer and provider contract strategy decisions with cloud-based modeling, scenario planning and analytics. Though contracting is an incredibly vital piece of a life sciences company’s U.S. launch and access journey, constructing and evolving optimal contracting strategy is challenging. There are many scenarios and variables to evaluate when establishing the placement and targeting of contract value and investment.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, releases a white paper entitled Global Market Access Trends: 2022 Edition that identifies the five key market access trends that life sciences executives should understand to ensure their organizations are prepared for the year ahead.

Annual J.P. Morgan Healthcare Conference, January 10, 2023 – Trinity Life Sciences, a global leader in life sciences solutions, and Havas Health & You (HHY&Y), the world’s largest global health and wellness network and part of Havas Group, a Vivendi (VIV) business, today announced a strategic partnership that will allow both companies to offer cohesive end-to-end commercial solutions to the life sciences industry. The partnership includes Havas Health & You taking a minority investment in Trinity.

Trinity Life Sciences, a global leader in life sciences solutions, today announced the appointment of Paul R. Lucchese as General Counsel and a member of the executive operating committee, reporting directly to Rebecca McNamara, Trinity’s Chief Financial Officer and Head of Corporate Operations. He will be responsible for leading Trinity’s legal operations and global compliance activities.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, reports that inclusion on the National Reimbursement Drug List (NRDL) offers substantial opportunities for innovative, clinically differentiated therapies in China despite steep price reductions. According to a new white paper entitled Cracking the Code of the Access Landscape in China: Analysis of the 2021 NRDL Update, the average annual sales for newly listed products on the 2018 -2020 NRDL were two to three times higher in the first year post-NRDL compared to pre-NRDL. The 67 newly listed branded products on the 2021 NRDL received a ~62% price reduction on average, maintaining the ~60% average price reduction trends since 2018.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, has made available its TGaS Advisors’ brief “What You Need To Know To Be Prepared for 2023” and its podcast episode “What Leaders In Life Sciences Need To Know To Be Prepared for 2023” based on highlights presented at the TGaS Advisors’ 2022 Fall Client Summit. The TGaS 2022 Fall Client Summit was held in October at the W Hotel Philadelphia with nearly 200 attendees from 100 life sciences companies, the largest in-person Summit to date.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, sees competitive intelligence (CI) leaders in life sciences moving beyond data mining and monitoring to deliver accurate, robust insights. As there is more information becoming available at an ever-increasing pace, it has become more difficult to sift through and find actionable CI. Trinity’s Dynamic Market Intelligence Center of Excellence conducted a qualitative study, speaking to 14 CI Leaders (those who have ownership of CI) and 7 CI Partners (those who are key stakeholders and the principal recipients of the intelligence), to find out how CI teams are optimizing their strategic value with process and approach.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, released its second annual TGaS Digital Marketing Competency Report assessing 160+ biopharma brands through the lens of digital patient experiences. The novel study evaluates the brands across five categories and 60 unique metrics to understand each one’s digital marketing presence.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces Quick Payer Pulse—a proprietary survey tool that generates and quantifies country-specific payer insights to support time-sensitive business needs. In life sciences, pricing and access are vital to an asset’s success globally. As assets go through earlier development phases or M&A processes, there are many situations where a payer pulse-check is needed to make efficient, informed decisions.

Trinity Life Sciences:

Trinity Life Sciences, a leader in global life sciences commercialization solutions, outlines a new approach to Patient Journey that allows patient-centric organizations to engage on a meaningful level with patients. As patients continue to expand their role in healthcare choice and treatment decision-making, expectations have grown for pharma to provide an experience in line with well-known, customer-centric consumer brands. To reach this level of engagement and experience design with patients, life sciences organizations need insight into the patient’s holistic journey from all relevant dimensions—not just their clinical pathway through care.

Trinity Life Sciences, a global leader in life sciences solutions, today announced the appointment of Maia Germain as Chief People Officer (CPO) and a member of the executive operating committee, reporting directly to Rebecca McNamara, Trinity’s CFO and Head of Corporate Operations.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced it was named to the 2022 Inc. 5000 fastest-growing private companies list. This is the second year in a row Trinity has been included on the prestigious list. The Inc. 5000 list represents a one-of-a-kind look at the most successful companies within the economy’s most dynamic segment – its independent businesses.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced it signed an asset purchase agreement for the acquisition of Vancery’s customer research technology. The investment expands Trinity’s insights and analytics product offerings, allowing the company to better connect with healthcare professionals to inform commercial strategy for its clients. The new technology will improve primary market research in the life sciences by integrating advanced research methods with an enhanced respondent experience to drive higher quality insights.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced the acquisition of Illinois-headquartered D Cube Analytics. The acquisition adds extensive data science and digital transformation capabilities to Trinity’s growing commercialization portfolio. D Cube’s bespoke analytics platforms, purpose built for life sciences companies, help extract maximum value out of data investments and facilitate decision-making to achieve commercial outcomes more effectively and efficiently.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, reports that 62 percent of biopharma products that launched between September 2019 and December 2021 underperformed expectations, including 24 out of 28 non-rare, non-oncology products. According to a new white paper entitled Empowering the Next-Generation Launch Model, commercial teams in life sciences need a more gradual, stepwise approach to product launches to achieve success.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, released its latest TGaS report entitled, Reimagining Work Models in the Life Sciences: Implications for the Future of Work. The study is the first of its kind for the life sciences industry as it provides objective data to help companies make informed decisions about how and where employees should work. The paper finds that remote working did not have any negative impact on perceived achievement of intended outcomes. In fact, employees rated achievement of intended work outcomes 16% higher when working remotely/virtually and positive impact on work-life balance, development, autonomy, connectedness and contribution was rated up to 54% higher.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, maps out the complexities life sciences companies are grappling with as they pull the “idea” of patient centricity through to execution and measurable results. While the vision and goal of patient centricity are clear, the challenge is crafting concrete steps to integrate the patient voice throughout the product lifecycle and the organization. The new advisory brief entitled Patient Centricity: Optimizing Integration throughout the Lifecycle discusses approaches, models and actions that address some of the most common questions:

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced the launch of Government Pricing (GP) services within TGaS Advisors. The new services help pre-commercial and emerging life sciences companies develop their GP policies and methodologies and provide support for ongoing GP calculations. Because drug pricing in the U.S. remains at the forefront of debates in Congress, rules and regulations continue to be dynamic, which poses compliance risks for drug manufacturers. GP calculations can also have a significant impact on a company’s bottom line if not carefully considered.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announces the opening of its next-generation office space in Gurgaon, India. The opening of the new office is part of Trinity’s ongoing commitment to support development and innovation in the Asia-Pacific region.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, has been named to Inc.’s annual Best Workplaces list. Featured in the May/June 2022 issue, hitting newsstands on May 17, 2022, and prominently featured on Inc.com, the list is the result of a comprehensive measurement of American companies that have excelled in creating exceptional workplaces and company culture.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, explores the implications of significant evolution and growth in the U.S. Health Economics and Outcomes Research (HEOR) field over the last decade. Many changes have been driven by payers, regulators and clinicians who are increasingly looking to HEOR and Real-World Evidence (RWE) as a valuable source for patient-level data. The new white paper entitled Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR explores a multi-disciplinary view on where and how HEOR experts see the field evolving. The analysis aims to better understand how HEOR capabilities can be best leveraged across the life sciences industry to improve patient outcomes.

Trinity Life Sciences, a leader in global life sciences commercialization solutions released its latest TGaS Landscape report entitled, Commercial and Medical Affairs Leaders Landscape 2022. The report finds that in order to optimize the effectiveness between Commercial and Medical Affairs, a dynamic approach to collaboration among teams is necessary. Building processes together and supporting a ‘one company’ mindset fosters a winning culture and contributes to a product’s success.

Trinity Life Sciences, a leader in global life sciences solutions, conducted research to explore the importance and impact of Competitive Intelligence (CI) from the perspective of pharma clinical and commercial teams. A changing competitive environment and rapidly proliferating data streams have made relevant, actionable market intelligence critical for life science companies. Organizations that rapidly contextualize, interpret and apply strategic reasoning are better able to optimize market positioning, make data-driven business development decisions and avoid suboptimal investments.

Trinity Life Sciences, a leader in global life sciences solutions, recognizes the vital importance of the Voice of the Patient across the entire product lifecycle. Trinity’s patient focus has evolved over 25 years, with the formation of the Patient Centricity Center of Excellence (COE) in 2019 to recognize the growing importance and involvement of patients as a healthcare stakeholder. Trinity’s dedicated patient-focused team actively integrates all of Trinity’s patient offerings, including tech-enabled services, to support life sciences’ drive to adopt a patient-centric approach.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, has made available its TGaS Advisors’ brief “What You Need To Know Now To Be Prepared For 2022” based on highlights it presented at the TGaS Advisors’ 2021 Fall Virtual Summit. The TGaS 2021 Fall Virtual Summit was held in November with over 450 attendees, the largest Summit to date.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, conducted research on Women Representation in Life Science Consulting Leadership and finds there is a lack of women in senior, decision-making roles. The white paper analyzed 64 US-based consulting firms with life science practices to establish number of leaders and gender breakdown, as well as indicators for diversity, equity and/or inclusion (DEI) and gender equity efforts.

Trinity Life Sciences, a leader in global life sciences solutions, announces the creation of the new Dynamic Market Intelligence Center of Excellence (COE). The new COE offers life sciences companies both expert- and tech-driven solutions for the most pressing challenges facing today’s competitive intelligence (CI) departments. Trinity’s experts leverage years of commercialization experience to deliver effective insights that help clients maximize their impact, differentiate and develop winning strategies.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, launched its inaugural TGaS 2021 Digital Competency Report assessing 124 biopharma patient brands through the lens of digital execution. The novel study evaluates the brands across five categories and 40 unique metrics to understand each one’s digital presence.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced today the signing of a definitive agreement for a recapitalization transaction led by Kohlberg & Company, a leading private equity firm with more than 30 years of experience. Trinity has been partnered with Parthenon Capital since early 2018 to rapidly grow its team, capabilities and global footprint. This recapitalization will provide Trinity with a new capital partner with similarly deep experience supporting growth-oriented life sciences companies and will enable the Company to continue its focus on global expansion and offering its life sciences client base innovative new products and services. Trinity’s management team, led by CEO David Fitzhenry, will continue to lead the organization through its ongoing strategic growth.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, today announced that Rebecca McNamara, Chief Financial Officer at Trinity, will be a featured speaker at the 19th annual MIT Sloan CFO Summit, the nation’s premier one-day CFO conference. This year’s conference, titled “Optimism and Excellence,” features the role of CFOs in uplifting their companies and instilling enterprise excellence.